7 research outputs found
Discovery and validation of prognostic tissue markers in clinical prostate cancer
Samenvatting
Prostaatkanker is divers: in klinische presentatie, in histomorfologische tumor groeipatronen en in overlevingsstatistieken. Momenteel wordt een aantal markers voor prostaatkanker beschreven die het klinisch gedrag van de tumor beter kunnen voorspellen. De meeste markers zijn onderzocht in patiënten die operatief behandeld werden. Om een significant effect te kunnen bewerkstelligen op de therapeutische beslissing is het echter belangrijk dat markers ook getest worden op diagnostische prostaat naaldbiopten.
CRISP3 en β-MSP zijn uitgebreid beschreven. β-MSP expressie neemt af en CRISP3 expressie neemt toe in meer hooggradige tumoren. Daarnaast worden zij beschreven als onafhankelijke voorspellers van prostaatkanker recidief na operatie. Wij hebben deze markers getest op een cohort van prostaat naaldbiopten. Beide markers toonden geen voorspellende waarde in de naaldbiopten voor de ernst van prostaatkanker in de totale prostaat van diez
Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review
Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual assessment of a tumor's aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer
The Gleason score (GS) of prostate cancer on diagnostic biopsies is an important
parameter for therapeutic decision-making. Biopsy GS under-estimates the actual GS at
radical prostatectomy in a significant number of patients due to sampling artifact. The
aim of this study was to identify markers that are differentially expressed in Gleason
grade 3 (GG3) tumor glands embedded in GS 4 + 3 = 7 and GS 3 + 3 = 6 prostate
cancer using laser capture microdissection and RNA sequencing.
GG3 tumor glands embedded in nine GS 3 + 3 = 6 and nine GS 4 + 3 = 7 prostate
cancers were isolated by laser capture microdissection of frozen radical prostatectomy
specimens. After RNA amplification and RNA sequencing, differentially expressed genes
in both GG3 components were identified by a 2log fold change > 1.0 and p-value < 0.05.
We applied immunohistochemistry on a tissue micro-array representing 481 radical
prostatectomy samples for further validation on protein level.
A total of 501 genes were up-regulated and 421 down-regulated in GG3 glands
embedded in GS 4 + 3 = 7 as compared to GS 3 + 3 = 6 prostate cancer. We selected
HELLS, ZIC2 and ZIC5 genes for further validation. ZIC5 mRNA was up-regulated 17 fold
(p = 8.4E–07), ZIC2 8 fold (p = 1.3E–05) and HELLS 2 fold (p = 0.006) in GG3 glands
derived from GS 4 + 3 = 7. HELLS expression of ≥ 1% occurred in 10% GS < 7, 17% GS 7
and 43% GS >7 prostate cancer (p < 0.001). Using a cut-off of ≥ 1%, protein expression
of ZIC5 was present in 28% GS 7 cancer (p < 0.001).
ZIC2 was neither associated with GS nor outcome in our validation set. HELLS was
independently predictive for biochemical-recurrence after radical prostatectomy
(HR 2.3; CI 1.5–3.6; p < 0.01).
In conclusion, HELLS and ZIC5 might be promising candidate markers for selection
of biopsy GS 6 prostate cancer being at risk for up-grading at prostatectomy
Genome-wide Investigation of multifocal and unifocal prostate cancer-are they Genetically different?
Prostate cancer is widely observed to be biologically heterogeneous. Its heterogeneity is manifested histologically as multifocal prostate cancer, which is observed more frequently than unifocal prostate cancer. The clinical and prognostic significance of either focal cancer type is not fu
Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy
Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
Although many patients are cured from prostate cancer (PCa) by surgery only, there are still patients who will experience rising prostate-specific antigen (PSA) levels after surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic markers in PCa tissue might enable finding better treatment for those patients experiencing BCR with a high chance of metastasis. In this study, we aimed to identify altered proteins in prostate cancer tissue, and to evaluate their potential role as prognostic markers. We used two proteomics strategies to analyse 34 prostate tumours (PCa) and 33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic markers of the disease. Tissue microarray immunohistochemical staining indicated that a low percentage of positive tumour cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93)), and a low percentage of positive tumour cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-5.22)) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value for PCa
Low-molecular-weight protein tyrosine phosphatase predicts prostate cancer outcome by increasing the metastatic potential
Background Low-risk patients suffering from prostate cancer (PCa) are currently placed under active surveillance rather than undergoing radical prostatectomy. However, clear parameters for selecting the right patient for each strategy are not available, and new biomarkers and treatment modalities are needed. Low-molecular-weight protein tyrosine phosphatase (LMWPTP) could present such a target. Objective To correlate expression levels of LMWPTP in primary PCa to clinical outcome, and determine the role of LMWPTP in prostate tumor cell biology. Design, setting, and participants Acid phosphatase 1, soluble (ACP1) expression was analyzed on microarray data sets, which were subsequently used in Ingenuity Pathway Analysis. Immunohistochemistry was performed on a tissue microarray containing material of 481 PCa patients whose clinicopathologic data were recorded. PCa cell line models were used to investigate the role of LMWPTP in cell proliferation, migration, adhesion, and anoikis resistance. Outcome measurements and statistical analysis The association between LMWPTP expression and clinical and pathologic outcomes was calculated using chi-square correlations and multivariable Cox regression analysis. Functional consequences of LMWPTP overexpression or downregulation were determined using migration and adhesion assays, confocal microscopy, Western blotting, and proliferation assays. Results and limitations LMWPTP expression was significantly increased in human PCa and correlated with earlier recurrence of disease (hazard ratio [HR]:1.99; p < 0.001) and reduced patient survival (HR: 1.53; p = 0.04). Unbiased Ingenuity analysis comparing cancer and normal prostate suggests migratory propensities in PCa. Indeed, overexpression of LMWPTP increases PCa cell migration, anoikis resistance, and reduces activation of f